
Aiforia
Total Raised
$25.37MInvestors Count
8Deal Terms
1Funding, Valuation & Revenue
6 Fundings
Aiforia has raised $25.37M over 6 rounds.
Aiforia's latest funding round was a IPO for on December 10, 2021.
Aiforia's 2021 revenue was $1.13M. Aiforia's most recent revenue is from 2021.
Sign up for a free demo to see revenue data from 2021 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/10/2021 | IPO | 1 | ||||
6/3/2021 | Series B | $1.13M FY 2021 | ||||
3/5/2020 | Incubator/Accelerator | |||||
11/18/2019 | Grant | |||||
12/1/2017 | Series A |
Date | 12/10/2021 | 6/3/2021 | 3/5/2020 | 11/18/2019 | 12/1/2017 |
|---|---|---|---|---|---|
Round | IPO | Series B | Incubator/Accelerator | Grant | Series A |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | $1.13M FY 2021 | ||||
Sources | 1 |
Aiforia Deal Terms
1 Deal Term
Aiforia's deal structure is available for 1 funding round, including their Series A from December 01, 2017.
Round | Series A |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
Aiforia Investors
8 Investors
Aiforia has 8 investors. PHC Holdings invested in Aiforia's Series B funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
6/3/2021 | 6/3/2021 | 1 Series B | Corporation | Japan | ||
Bank | Finland | |||||
Incubator/Accelerator | California | |||||
Government | Belgium | |||||
Venture Capital | Hong Kong |
First funding | 6/3/2021 | ||||
|---|---|---|---|---|---|
Last Funding | 6/3/2021 | ||||
Investor | |||||
Rounds | 1 Series B | ||||
Board Seats | |||||
Type | Corporation | Bank | Incubator/Accelerator | Government | Venture Capital |
Location | Japan | Finland | California | Belgium | Hong Kong |
Compare Aiforia to Competitors

AIRA Matrix provides artificial intelligence solutions for the healthcare and life sciences sectors, offering digital pathology as a service, custom AI development, and tools for drug discovery, preclinical research, and clinical applications. The focus is on enhancing efficiency, diagnostic accuracy, and turnaround times in pathology laboratory workflows, as well as supporting disease stratification and management in cancer care. It was founded in 2011 and is based in Mumbai, India.

PathAI provides artificial intelligence (AI)-powered research tools and services for pathology. It delivers the diagnosis and treatment of cancer by leveraging modern approaches in machine learning. The company offers biopharmacy lab services, clinical development services, drug and diagnostic development, and more. It was founded in 2016 and is based in Boston, Massachusetts.

Mindpeak specializes in artificial intelligence for clinical pathology within the healthcare sector. The company offers diagnostic software that aids in clinical pathology and provides analysis of tissue samples. Mindpeak's products are used in pathology labs and clinical research. It was founded in 2018 and is based in Hamburg, Germany.

Ibex focuses on AI-based cancer diagnostics within the healthcare sector, particularly in pathology. The company provides diagnostic solutions that assist pathologists in detecting cancer and other features in tissue samples, with the objective of supporting the accuracy and efficiency of cancer diagnosis. Ibex serves the healthcare and medical diagnostics industry, with attention to the workflow and capabilities of pathologists. It was founded in 2016 and is based in Tel Aviv, Israel.
Aiosyn focuses on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Azra AI focuses on healthcare technology with an emphasis on automating oncology workflows. The company provides artificial intelligence (AI) solutions that identify cancer diagnoses and incidental findings in real-time, automate cancer registry processes, and facilitate tumor board case management. The platform aims to enhance patient care management, offer reporting and analytics, and provide clinical consulting services, serving the healthcare and oncology sectors. Azra AI was formerly known as Invenero Holdings. It was founded in 2022 and is based in Nashville, Tennessee.
Loading...

